Clinical and biological implications of driver mutations in myelodysplastic syndromes.
By E. Papaemmanuil, Moritz Gerstung, L. Malcovati, S. Tauro, G. Gundem, P. van Loo, Christopher J. Yoon, Peter Ellis, David C. Wedge, A. Pellagatti and 28 more. Blood, 2013
1,780 citations recorded by the source corpus.
Subfields: Genetics, Hematology
View Paper: https://www.semanticscholar.org/paper/05848a1421a8785ee7d4a95697fa38b94c3f5878
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Genetics
- Charles Swanton
- Florian Markowetz
- Benjamin L. Ebert
- Roland F. Schwarz
- Niko Beerenwinkel
- Moritz Gerstung
- Peter J. Campbell
- Siddhartha Jaiswal
In Hematology
Citations in the corpus
- Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms. (2014, neutral): “Neutrophils (10(9)/L) average (range) 9 (2-36) 6 (3-16) 8 (3-21)”
- Genomic Classification and Prognosis in Acute Myeloid Leukemia (2016, methodology): “DNMT3A TET2 ASXL1 inv(16) t(15;17) t(8;21) t(11q23;x) inv(3) t(6;9)”
- Biological and therapeutic impact of intratumor heterogeneity in cancer evolution. (2015, background): “Similarly, in MDS, the type of early driver mutations can dictate the future trajectories of disease evolution (Papaemmanuil et al., 2013).”
- Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes. (2015, background): “(1) Dana-Farber Cancer Institute and Brigham and Women's Hospital Boston, Massachusetts USA (2) Moores Cancer Center at the University of California, San Diego La Jolla, California USA (3) Cleveland Clinic Taussig Cancer Institute Cleveland, Ohio USA (4) Massachusetts General Hospital Boston, Massac”
- Age-related clonal hematopoiesis associated with adverse outcomes. (2014, neutral): “Sequencing studies have identified a set of recurrent mutations in several types of hematologic cancers.(12-24) However, the frequency of these somatic mutations in the general population is unknown.”
- Cancer Evolution: Mathematical Models and Computational Inference (2014, background): “Similarly, subclonal driver mutations have recently been identified that comprise risk factors for rapid disease progression in in chronic lymphocytic leukemia (Landau et al. 2013) and myelodysplasia (Papaemmanuil et al. 2013).”